AI-generated analysis, not investment advice. The articles are written by AI, edited, and checked against company filings — but the judgements are opinions and the figures go stale. How this is made · Terms

No Backlog, Only PrescriptionsNarrow moat

Gilead Sciences (GILD) — moat facet

Gilead has no order backlog; its forward book is millions of HIV patients refilling every month.

Unlike an equipment maker, Gilead has no backlog to report. It sells medicines through wholesalers who order to meet pharmacy demand, and its filings disclose no order backlog or remaining performance obligation for product sales. The US wholesalers "with whom we have entered into inventory management agreements make estimates to determine end-user demand"1, which is as close to a forward book as the business gets.

Gilead 2026 product sales guidance, midpoint ($bn)29.8Feb 202630.2May 202630.25Aug 2026Gilead Q4 2025, Q1 2026 and Q2 2026 results releases
Guidance has risen twice this year.

That is less risky than it sounds. The real backlog is the patients: people on HIV treatment refill every month, and Gilead's HIV sales have fallen in only one year since 201923. A chronic medicine with stable patients behaves like contracted revenue without the contract.

The absence of a backlog does make quarters noisy. Gilead warns that changes in wholesaler inventory "can cause our operating results to fluctuate unexpectedly"4, and receivables tell the same story: about 60% of accounts receivable at 30 June 2026 related to the three largest wholesalers5. Accounts receivable were $5,055 million6.

For an owner the useful reading is to ignore the quarter and watch the year. Gilead guides product sales of $30.1 to $30.4 billion for 20267, a forecast built on prescriptions, not orders.

There is one asset that looks a little like a backlog: stock built ahead of approval. Gilead held about $568 million of pre-commercial inventory at 30 June 20268, product made before regulators decide on it. If the launches it was built for are delayed, that inventory is the first casualty.

The missing backlog becomes a problem only if prescriptions fall. If full-year product sales come in below the bottom of guidance, $30.1 billion, the patient base will have weakened rather than the wholesalers' stock.

Moat trajectory: Holding steady

2026 product sales guidance raised to $30.1-30.4bn.

The number that tests this moat
Reported
2026 product sales guidance, latest
$30.1-30.4bn (4 August 2026), raised from $29.6-30.0bn in February

The forecast that stands in for a backlog; missing the bottom would mean the patient base weakened.

Source: Gilead Sciences Q2 2026 results release ↗
References
  1. ReportedThe US wholesalers "with whom we have entered into inventory management agreements make estimates to determine end-user demand", which is as close to a forward book as the business gets.
    Gilead Sciences Form 10-K for 2025 - customers, wholesalers, distribution and gross-to-net deductions. — FY2025 · publ. 24 February 2026 · source ↗
  2. ReportedThe real backlog is the patients: people on HIV treatment refill every month, and Gilead's HIV sales have fallen in only one year since 2019.
    Gilead Sciences Form 10-K for 2021 - revenue by product for 2019-2021, including HCV, HBV/HDV, Cell Therapy, Trodelvy and Veklury, and the 2019-2021 wholesaler table. — FY2021 · publ. February 2022 · source ↗
  3. ReportedThe real backlog is the patients: people on HIV treatment refill every month, and Gilead's HIV sales have fallen in only one year since 2019.
    Gilead Sciences Form 10-K for 2025 - revenue by product, product group and region (Note 2) and the MD&A discussion of product sales. — FY2025 · publ. 24 February 2026 · source ↗
  4. ReportedGilead warns that changes in wholesaler inventory "can cause our operating results to fluctuate unexpectedly", and receivables tell the same story: about 60% of accounts receivable at 30 June 2026 related to the three largest wholesalers.
    Gilead Sciences Form 10-Q for the quarter ended 30 June 2026 - acquired IPR&D for Arcellx, Tubulis and Ouro, the $1.75 billion Trodelvy impairment, debt, receivables and the December 2025 agreement with the US administration. — Q2 2026 · publ. 6 August 2026 · source ↗
  5. ReportedGilead warns that changes in wholesaler inventory "can cause our operating results to fluctuate unexpectedly", and receivables tell the same story: about 60% of accounts receivable at 30 June 2026 related to the three largest wholesalers.
    Gilead Sciences Form 10-Q for the quarter ended 30 June 2026 - acquired IPR&D for Arcellx, Tubulis and Ouro, the $1.75 billion Trodelvy impairment, debt, receivables and the December 2025 agreement with the US administration. — Q2 2026 · publ. 6 August 2026 · source ↗
  6. ReportedAccounts receivable were $5,055 million.
    Gilead Sciences Form 10-Q for the quarter ended 30 June 2026 - acquired IPR&D for Arcellx, Tubulis and Ouro, the $1.75 billion Trodelvy impairment, debt, receivables and the December 2025 agreement with the US administration. — Q2 2026 · publ. 6 August 2026 · source ↗
  7. ReportedGilead guides product sales of $30.1 to $30.4 billion for 2026, a forecast built on prescriptions, not orders.
    Gilead Sciences second-quarter 2026 results release, Form 8-K exhibit 99.1 - revenue by product, income statement, cash flow, balance sheet, pipeline updates and 2026 guidance - income statement, EPS, cash flow, balance sheet and 2026 guidance. — Q2 2026 · publ. 4 August 2026 · source ↗
  8. ReportedGilead held about $568 million of pre-commercial inventory at 30 June 2026, product made before regulators decide on it.
    Gilead Sciences Form 10-Q for the quarter ended 30 June 2026 - acquired IPR&D for Arcellx, Tubulis and Ouro, the $1.75 billion Trodelvy impairment, debt, receivables and the December 2025 agreement with the US administration. — Q2 2026 · publ. 6 August 2026 · source ↗
Sources
Generated October 4, 2026